Next Article in Journal
Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease
Previous Article in Journal
Changes in the Fecal Metabolome Are Associated with Feeding Fiber Not Health Status in Cats with Chronic Kidney Disease
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Development and Validation of a Highly Sensitive LC-MS/MS Method for the Analysis of Bile Acids in Serum, Plasma, and Liver Tissue Samples

Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
*
Author to whom correspondence should be addressed.
Metabolites 2020, 10(7), 282; https://doi.org/10.3390/metabo10070282
Submission received: 22 June 2020 / Revised: 6 July 2020 / Accepted: 7 July 2020 / Published: 9 July 2020

Abstract

Bile acids control lipid homeostasis by regulating uptake from food and excretion. Additionally, bile acids are bioactive molecules acting through receptors and modulating various physiological processes. Impaired bile acid homeostasis is associated with several diseases and drug-induced liver injury. Individual bile acids may serve as disease and drug toxicity biomarkers, with a great demand for improved bile acid quantification methods. We developed, optimized, and validated an LC-MS/MS method for quantification of 36 bile acids in serum, plasma, and liver tissue samples. The simultaneous quantification of important free and taurine- and glycine-conjugated bile acids of human and rodent species has been achieved using a simple workflow. The method was applied to a mouse model of statin-induced myotoxicity to assess a possible role of bile acids. Treatment of mice for three weeks with 5, 10, and 25 mg/kg/d simvastatin, causing adverse skeletal muscle effects, did not alter plasma and liver tissue bile acid profiles, indicating that bile acids are not involved in statin-induced myotoxicity. In conclusion, the established LC-MS/MS method enables uncomplicated sample preparation and quantification of key bile acids in serum, plasma, and liver tissue of human and rodent species to facilitate future studies of disease mechanisms and drug-induced liver injury.
Keywords: bile acid; LC-MS; statin myotoxicity; biomarker; adverse drug effect; disease bile acid; LC-MS; statin myotoxicity; biomarker; adverse drug effect; disease
Graphical Abstract

Share and Cite

MDPI and ACS Style

Gómez, C.; Stücheli, S.; Kratschmar, D.V.; Bouitbir, J.; Odermatt, A. Development and Validation of a Highly Sensitive LC-MS/MS Method for the Analysis of Bile Acids in Serum, Plasma, and Liver Tissue Samples. Metabolites 2020, 10, 282. https://doi.org/10.3390/metabo10070282

AMA Style

Gómez C, Stücheli S, Kratschmar DV, Bouitbir J, Odermatt A. Development and Validation of a Highly Sensitive LC-MS/MS Method for the Analysis of Bile Acids in Serum, Plasma, and Liver Tissue Samples. Metabolites. 2020; 10(7):282. https://doi.org/10.3390/metabo10070282

Chicago/Turabian Style

Gómez, Cristina, Simon Stücheli, Denise V. Kratschmar, Jamal Bouitbir, and Alex Odermatt. 2020. "Development and Validation of a Highly Sensitive LC-MS/MS Method for the Analysis of Bile Acids in Serum, Plasma, and Liver Tissue Samples" Metabolites 10, no. 7: 282. https://doi.org/10.3390/metabo10070282

APA Style

Gómez, C., Stücheli, S., Kratschmar, D. V., Bouitbir, J., & Odermatt, A. (2020). Development and Validation of a Highly Sensitive LC-MS/MS Method for the Analysis of Bile Acids in Serum, Plasma, and Liver Tissue Samples. Metabolites, 10(7), 282. https://doi.org/10.3390/metabo10070282

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop